How we approach thrombosis risk in children with COVID-19 infection and MIS-C
- PMID: 33955167
- PMCID: PMC8206673
- DOI: 10.1002/pbc.29049
How we approach thrombosis risk in children with COVID-19 infection and MIS-C
Abstract
Thrombosis within the microvasculature and medium to large vessels is a serious and common complication among critically ill individuals with coronavirus disease 2019 (COVID-19). While children are markedly less likely to develop severe disease than adults, they remain at risk for thrombosis during acute infection and with the post-acute inflammatory illness termed multisystem inflammatory syndrome in children. Significant knowledge deficits in understanding COVID-19-associated coagulopathy and thrombotic risk pose clinical challenges for pediatric providers who must incorporate expert opinion and personal experience to manage individual patients. We discuss clinical scenarios to provide framework for characterizing thrombosis risk and thromboprophylaxis in children with COVID-19.
Keywords: COVID-19; MIS-C; anticoagulation; thrombosis.
© 2021 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.
Conflict of interest statement
The authors declare that there is no conflict of interest relevant to this publication.
Figures

References
-
- Datta SD, Talwar A, Lee JT. A proposed framework and timeline of the spectrum of disease due to SARS‐CoV‐2 infection: illness beyond acute infection and public health implications. JAMA. 2020;324(22):2251‐2252. - PubMed
-
- Duarte‐Salles T, Vizcaya D, Pistillo A, et al. Baseline characteristics, management, and outcomes of 55,270 children and adolescents diagnosed with COVID‐19 and 1,952,693 with influenza in France, Germany, Spain, South Korea and the United States: an international network cohort study. medRxiv. 10.1101/2020.10.29.20222083 - DOI
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical